1. Catalogs
  2. ZAP Surgical Systems Inc
  3. A Comparison of Whole-Brain Dose During

A Comparison of Whole-Brain Dose During

A Comparison of Whole-Brain Dose During
1 / 14 PagesView full catalog

A Comparison of Whole-Brain Dose During

Product catalog summary
Abstract: Stereotactic radiosurgery (SRS) is preferred for treating multiple brain metastases due to its precision, minimizing damage to healthy brain tissue compared to whole-brain radiotherapy (WBRT). This study evaluates radiation dose to uninvolved brain tissue across various SRS platforms using a standardized imaging dataset. Findings indicate that dedicated cranial SRS devices result in less irradiation of uninvolved brain tissue than multi-purpose systems.

Introduction: SRS is favored over WBRT for brain metastases treatment due to reduced neurocognitive damage. The study compares dosimetric differences among SRS technologies, focusing on dose conformity, gradient indices, and the volume of brain receiving doses above 12 Gy (V12 Gy), which predicts radiation-induced brain injury (RIBI).

Materials and Methods: A de-identified CT and MRI dataset from a patient with 10 brain metastases was used. Treatment plans were created using various SRS platforms, including Varian TrueBeam, Accuray CyberKnife, Elekta Gamma Knife, and ZAP Surgical ZAP-X. Each platform's treatment plan was analyzed for dose coverage and minimization of radiation to uninvolved brain tissue.

Results: The study compared seven treatment planning and dosimetric parameters across six SRS systems. Dedicated cranial SRS systems, such as the Gamma Knife and ZAP-X, provided better protection to uninvolved brain tissue compared to multi-purpose LINAC systems.

Specifications and Procedures: The document compares multi-purpose C-arm and full-body robotic delivery platforms with dedicated cranial SRS platforms like CyberKnife and Gamma Knife. Key parameters include prescription dose, GTV-PTV margin expansion, isocenter configurations, beam array, beam energy, source-axis distance, collimation, target max dose, and whole brain radiation exposure (V12, V10, V5).

Findings: Dedicated cranial SRS platforms, such as Gamma Knife, show significantly lower radiation exposure to the uninvolved brain compared to multi-purpose systems. The study notes a 50-fold variation in V5 Gy exposure, with dedicated platforms minimizing exposure more effectively.

Discussion: The document discusses reasons for higher whole brain exposure in multi-purpose systems, including collimator leakage, larger source-axis distance, and higher scatter beam energy. It emphasizes the trade-off between treatment speed and quality.

Limitations: The study is based on a single patient dataset and does not account for variability in clinical practice. It is purely dosimetric and does not evaluate the clinical impact of lower-dose exposures on neurocognitive function.

Conclusions: The study concludes that dedicated cranial radiosurgery platforms are superior in minimizing brain irradiation. It suggests focusing on V5 Gy, V10 Gy, and V12 Gy dose levels for future assessments of SRS platforms.

Recommendations: Future studies should examine the impact of low-dose brain radiation on cognitive function and quality of life. Researchers are encouraged to report on V5 Gy, V10 Gy, and V12 Gy levels in addition to traditional parameters like conformity index (CI) and gradient index (GI).
See more

Catalog excerpts

A Comparison of Whole-Brain Dose During-1

Open Access Technical Report Published via Stanford Neurosurgery A Comparison of Whole-Brain Dose During Stereotactic Radiosurgery for Multiple Metastases Across Technology Platforms Received 09/03/2025 Review began 09/04/2025 Neelan J. Marianayagam 1 , Ziyi Wang 2 , Alonso N. Gutierrez 3, 4, D Jay Wieczorek 4, Ian Paddick 5, Yusuke S. Hori 6 , David J. Park 6, Steven D. Chang 6, Stephanie Key 7 , Georg A. Weidlich 8 , John Adler 9, 6 Review ended 09/10/2025 Published 09/16/2025 © Copyright 2025 Marianayagam et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. DOI: 10.7759/cureus.92442 1. Neurosurgery, Stanford University, Stanford, USA 2. Radiation Oncology, Stanford Health Care Cancer Center, Palo Alto, USA 3. Radiation Oncology, Florida International University, Herbert Wertheim College of Medicine, Miami, USA 4. Radiation Oncology, Miami Cancer Institute, Miami, USA 5. Medical Physics, Medical Physics Limited, London, GBR 6. Neurosurgery, Stanford University School of Medicine, Stanford, USA 7. Sales and Marketing, ZAP Surgical Systems, Inc., San Carlos, USA 8. Medical Physics, ZAP Surgical Systems, Inc., San Carlos, USA 9. Radiation Oncology, ZAP Surgical Systems, Inc., San Carlos, USA Corresponding author: John Adler, [email protected] Abstract Stereotactic radiosurgery (SRS) is now the gold standard radiation technique for the treatment of multiple brain metastases. By virtue of its targeting accuracy, SRS, relative to whole-brain radiotherapy (WBRT), maximizes both the likelihood of tumor ablation while minimizing irradiation (injury) of the uninvolved brain. The extent to which the latter objective is accomplished varies among radiosurgery platforms. In this study, we used a standardized imaging dataset taken from a patient with 10 random brain metastases to calculate the radiation dose delivered to the uninvolved normal brain across a range of modern SRS delivery platforms. This analysis reveals that irradiation of the uninvolved brain is considerably less on dedicated cranial SRS devices compared to multi-purpose C-arm and full-body robotic systems. Given the growing recognition of lower-dose radiation’s deleterious effects, these findings may have relevance to patient and technology selection. Categories: Medical Physics, Radiation Oncology, Neurosurgery Keywords: gamma knife (gk) radiosurgery, gyroscopic radiosurgery, linac-based radiosurgery, stereotactic radiosurgery, treatment of brain metastases, whole brain radiation dose Introduction By virtue of minimizing neurocognitive damage, “highly focal” stereotactic radiosurgery (SRS) is now deemed superior to whole-brain radiotherapy (WBRT) in the treatment of multiple brain metastases [1-4]. Although the exact radiobiologic mechanism remains cryptic, “low-dose” radiation exposure appears to damage cerebrovasculature, increase neuroinflammation, and impair neurogenesis, which collectively alter normal brain functions [2]. The greater spatial precision and accuracy of SRS appear to lessen these highly deleterious side effects. However, the extent of uninvolved brain irradiation varies among radiation delivery platforms, especially in patients with multiple metastases. Despite the current ubiquity of brain SRS for brain metastases, little has been published quantifying the dosimetric differences among different radiosurgical devices. In this study, we seek to make a rigorous comparison among a wide range of SRS technologies that are commonly used to treat multiple brain metastases. The most widely used metrics for establishing the relative quality of radiosurgical treatment are dose conformity (CI) and gradient (GI) indices [5,6]. However, as a secondary and absolute measure, V12 Gy (the volume of brain receiving a dose of greater than 12 Gy) is also deemed an important predictor of radiationinduced brain injury (RIBI), which is clinically characterized by brain enhancement and edema on contrast magnetic resonance imaging (MRI) brain, and often accompanied by conclusive brain necrosis on histological examination [7]. Given that such damage has the obvious potential to cause cognitive decline and executive dysfunction, it is featured prominently in modern clinical trial designs and guidelines [7,8]. Nevertheless, even less severe forms of radiation injury have been shown to correlate with cognitive decline and impaired executive function, despite the absence of radiographic changes - with fractionated WBRT serving as a notable example. Furthermore, more recent animal research unambiguously demonstrates that lower radiation doses, e.g., as low as the V5 Gy, represent an even lower “non-lesional” threshold for altering local neural circuit activity and damaging brain function. These recent findings elevate the clinical importance of low-dose brain radiation far beyond anything that was previously appreciated [9]. As brain metastasis patients continue to live longer, and thus the incidence of new and recurrent metastatic brain disease grows, this phenomenon is of particular concern. In light of these new findings, lower doses of radiation “spillage” now merit special consideration when designing treatment plans for multi-metastasis patients. How to cite this article Marianayagam N J, Wang Z, Gutierrez A N, et al. (September 16, 2025) A Comparison of Whole-Brain Dose During Stereotactic Radiosurgery for Multiple Metastases Across Technology Platforms. Cureus 17(9): e92442. DOI 10.7

 Open the catalog to page 1
A Comparison of Whole-Brain Dose During-2

Published via Stanford Neurosurgery Technical Report Materials and methods A single de-identified contrast computerized tomography (CT) and contrast MRI (T1 MR slice thickness included 1.25 mm with 512x512 image resolution) obtained in a single patient with 10 widely dispersed brain metastases was obtained from Stanford University (Stanford, CA) and used throughout this study. Ten target volumes were identified as the gross tumor volumes (GTVs), ranging in maximum dimension from 2.1 mm to 5.0 mm, with a median of 3.3 mm, and in volume from 0.01 cm3 to 0.06 cm 3, with a median of 0.02 cm3. This...

 Open the catalog to page 2
*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.
About MedicalExpo
MedicalExpo is a marketplace that offers B2B players a complete experience, from product sourcing to purchase. MedicalExpo is an entity of VirtualExpo Group.